XML 130 R59.htm IDEA: XBRL DOCUMENT v3.23.3
Funding Arrangement - Additional Information (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 9 Months Ended
Jun. 30, 2023
Apr. 30, 2021
Jul. 31, 2019
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Funding Arrangement [Line Items]                
Grant income       $ 1,640 $ 157 $ 4,759 $ 1,006  
Cost Reimbursement Sub-Award Agreement                
Funding Arrangement [Line Items]                
Funding period of award to develop universal vaccine to prevent infections caused by Group A Strep bacteria     4 years          
Potential funding amount of award to develop vaccine to prevent shingella infections $ 4,600 $ 500            
Grant income       1,600 $ 200 4,800 $ 1,000  
Cost Reimbursement Sub-Award Agreement | Maximum                
Funding Arrangement [Line Items]                
Initial funding committed by award     $ 1,600          
Total funding committed by award, available upon achievement of development milestones     15,100          
Potential funding period of award to develop vaccine to prevent shingella infections 5 years 5 years            
CARB-X Agreement                
Funding Arrangement [Line Items]                
Grant receivable on unreimbursed, eligible costs incurred       $ 1,900   $ 1,900   $ 1,000
CARB-X Agreement | Maximum                
Funding Arrangement [Line Items]                
Initial funding committed by award     14,600          
CARB-X Agreement | Minimum                
Funding Arrangement [Line Items]                
Potential funding committed by award     $ 11,700